Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Explicit marketing towards GLP-1 users may therefore be a mistake, as that risks turning off others who are also looking for products that are nutrient dense, high protein, etc, but who may think the product being marketed is not for them
Healthcare System Implications The widespread adoption of GLP-1 medications presents both opportunities and challenges for healthcare systems: a) Cost-Benefit Calculations : Although the medications themselves are expensive (ranging from $900 to $1,300 monthly without insurance coverage), their potential to reduce obesity-related healthcare costs is substantial
The increase correlates directly with the launch of high-efficacy GLP-1 medications (Wegovy in 2021, Mounjaro and Zepbound in 2022-2023) and the associated cost pressure on plan sponsors
In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to peoples health and lives, and increasing public health care expenses
